Please provide your email address to receive an email when new articles are posted on . In TEMPO-1, fixed 5 mg and 15 mg doses of tavapadon improved outcomes in patients with Parkinson’s disease.
A pioneering study published in the International Journal of Molecular Sciences by researchers at Durham University has revealed promising results for a new treatment targeting motor neuron disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results